Full-Time

Medical Director

Patient Safety Physician

Posted on 11/1/2025

Deadline 12/31/25
AstraZeneca

AstraZeneca

10,001+ employees

Global pharmaceutical company developing prescription medicines

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • The candidate must hold a medical degree (for example, Doctor of Medicine or Bachelor of Medicine, Bachelor of Surgery).
  • The candidate must have at least two years of clinical experience post-registration.
  • A high level of medical competence is required, with the ability to balance medical excellence with industry standards to achieve business goals.
  • The candidate must have at least two years of Drug Development or Patient Safety experience, the majority of which should be in industry, with clear evidence of delivery.
Responsibilities
  • Working with the Safety Team, be responsible for the Clinical Safety strategy for assigned AstraZeneca-MedImmune drug projects and products throughout all stages of development and/or when on the market, including implementation and communication of the strategy at the project team/governance level.
  • Definition of identified and potential risks with high level mitigation and minimisation; proposals for mitigation minimisation measures; safety go-no go criteria for the clinical programme; input to TPP/TPC; ssafety submission strategies; response to regulatory safety queries and definition of the risk component of the benefit/risk assessment.
  • Reviews and endorses the core Patient Risk Management Plan (PRMP)/Core Patient Risk Log (CPRL).
  • Provides expertise to the medical content of the safety specification, pharmacovigilance plan and risk minimisation activities in the core PRMP, MedImmune dRMP, CPRL and globally reviewed LRMPs.
  • Represents PS on cross-functional Clinical Teams and/or Project Teams for developmental and/or marketed products.
  • Provides medical input to ensuring that risk-minimisation strategies are implemented appropriately in relevant documents such as product reference safety information.
  • Provides strategic clinical safety input into Clinical Development planning activities in accordance with PS Operating Model and Science Unit Service Level agreements.
  • Provides strategic and medical input to project specific safety requirements (PSSR). Reviews and provides technical input and approval for investigator brochures, protocols, informed consents, final study reports and external data monitoring committees as appropriate.
  • Provides input on cross-functional ad-hoc teams set up to address urgent and important safety issues.
  • May present safety information at clinical investigator and commercial meetings.
  • Facilitates establishment of a Safety Management Team/MedImmune Safety Review Team as necessary.
  • Involved in all safety surveillance activities, may include medical review of individual safety cases (providing medical expertise and judgement), signal detection, evaluation and SERM activities (or Medimmune equivalent) for all products in area or responsibility.
  • Provides medical input to regulatory supporting documentation for labelling updates.
  • Provides medical input into Identification and utilization of appropriate sources of information and database searches to retrieve relevant data for evaluation of signals.
  • Collaborates with external provider representatives in routine signal management activities.
  • Discusses the results of data evaluation with the Surveillance Team and/or appropriate key stakeholders, eg Patient Safety VP TA, QPPV/Deputy QPPV.
  • Provides medical input to deliver accurate and fit for purpose safety evaluation documents with clear conclusions in response to internal or regulatory authority requests for safety data.
  • Provides strategic input into responses to regulatory requests for local label deviations from the company core safety documentation.
  • In consultation with the PS scientist and Clinical representatives, prepares the Developmental Core Safety Information (DCSI) for assigned development products.
  • Provides medical input and review of periodic reports (eg PBRERs, PSURs, DSURs) and renewal documentation submitted to regulatory agencies.
  • Provides the patient safety contribution to global regulatory submissions (NDA, BLA, MAA etc) for new products, formulations or indications.
  • Contributes to and/or reviews the PS component of Safety Agreements.
  • Advises on the preparation of licensing agreements in therapeutic area of responsibility.
  • Participates in AZ internal meetings with project focus.
  • Participates in external regulatory and non-regulatory meetings including those with consultants and other companies such as licensing partners.
  • May assist in due diligence activities.
  • May provide support to AZ Legal for product liability litigation, as appropriate.
  • Accountable for maintaining personal readiness in response to internal audit or regulatory inspection.
  • Participates in, and may lead, a process improvement initiative team within PS.
  • May contribute to advancement of methodology and process by generating new ideas and proposals for implementation.
  • Raises concerns/issues to senior management in a timely, open and appropriate manner; ensures quality and integrity of issue/event being escalated.
  • May mentor and train junior members of the team in signal evaluation methodology, risk management and preparation of safety reports and other documents.
  • Collaborates effectively in cross-functional and cross-cultural project teams and environments, and work with external providers.
Desired Qualifications
  • Higher Medical Training in Pharmaceutical Medicine is desirable.
  • A Master of Science or Doctor of Philosophy in a scientific discipline is desirable.
  • Ability to work across Therapeut Areas and Functions is desirable.
  • Experience supervising Patient Safety colleagues is desirable.
  • Demonstrated ability to understand epidemiological data is desirable.

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology sales surged 16% to $6.8B in Q1 2026.
  • New Dublin API facility opened April 30, 2026, boosts manufacturing.
  • £300M UK investment resumes after UK-US deal raises NICE threshold.

What critics are saying

  • FDA panel rejected camizestrant May 9, 2026, derails breast cancer pipeline.
  • Oncology generates 45% revenue; safety issues collapse growth trajectory.
  • Trump MFN policy collapse voids UK pricing uplift, triggers capex freeze.

What makes AstraZeneca unique

  • AstraZeneca formed in 1999 merger of Astra AB and Zeneca Group.
  • Leads oncology with Imfinzi, Tagrisso, Enhertu driving 44% revenue.
  • Certified 17,000 employees in AI for drug discovery acceleration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

IDA Ireland
Apr 30th, 2026
AstraZeneca announces opening of new API manufacturing facility in Dublin

* home * latest news * press releases * AstraZeneca announces opening of new API manufacturing facility in Dublin. AstraZeneca announces opening of new API manufacturing facility in Dublin 30/04/2026 Ireland AstraZeneca today officially opened their new Active Pharmaceutical Ingredient (API) manufacturing facility in Dublin. This new facility demonstrates how advanced automation, AI, and innovative new technologies push the boundaries of science and manufacturing. It was developed with the support and collaboration of Ireland's investment agency, IDA Ireland. Taoiseach Micheál Martin said: "Investments like this state-of-the-art new manufacturing facility strengthen our healthcare and biopharma base, support high-quality employment, and help ensure medicines can be supplied to patients around the world. It is a significant vote of confidence in Ireland's life sciences ecosystem and in the highly skilled people who work across the sector. I warmly welcome AstraZeneca's continued commitment to Dublin and I commend IDA Ireland for its ongoing work in supporting and securing investments of this scale." Pam Cheng, Executive Vice President, Global Operations, IT & Chief Sustainability Officer, AstraZeneca said: "This cutting-edge API Commercialisation facility is an innovative and unique asset in its global operations network, and plays a key role in the development and launch of its new medicines across its oncology portfolio and beyond. Through advanced automation, AI and innovative new technologies, IDA Ireland is pushing the boundaries of science and manufacturing - enhancing speed, flexibility, and sustainability to deliver future therapies to patients. Thank you to all colleagues and partners for making this milestone a reality." Michael Lohan, CEO of IDA Ireland said: "Healthcare and biopharma remain a key growth driver within IDA Ireland's strategy, and investments like this new API facility underline Ireland's strength in advanced manufacturing, innovation and talent. We are delighted to support AstraZeneca as it continues to expand its operations in Dublin, creating high-value jobs and strengthening the resilience of global supply chains while delivering life-changing medicines for patients worldwide." You might also be interested in. West continues its investment in Ireland with Dublin manufacturing facility expansion. West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced an additional 330 roles as part of an expansion of its manufacturing site in Damastown, Dublin. West is supported by the Irish Government, through IDA Ireland. Novartis and Deciphex host roundtable about Ireland's AI sector to mark collaboration. Collaboration Between Novartis and Deciphex Harnesses AI For Drug Discovery and Development.

PR Newswire
Apr 10th, 2026
Ailux appoints Maria Belvisi, Ph.D., as Chief Scientific Officer.

Ailux appoints Maria Belvisi, Ph.D., as Chief Scientific Officer. Apr 09, 2026, 20:00 ET * Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision - a program that recently delivered landmark wins in two pivotal COPD trials * Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug development organization, targeting first clinical entry by 2027 * Professor Belvisi will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. SHANGHAI and LONDON, April 9, 2026 /PRNewswire/ - Ailux, an AI-native biotech company discovering and engineering next-generation biologics across multiple indications, today announced the appointment of Maria G. Belvisi, Ph.D. as Chief Scientific Officer. Professor Belvisi brings more than three decades of industry and academic leadership in drug research and development, including nearly a decade at AstraZeneca where she served as Senior Vice President, Research and Development, Respiratory & Immunology, BioPharmaceuticals R&D. She will report to Alex Li, Chief Executive Officer of Ailux. Ailux is an AI-native biotech company headquartered in Shanghai, founded within and wholly-owned by XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab and a global team of approximately 150 across China, the UK, and the US. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is advancing its internal pipeline toward first clinical entry by 2027. Professor Belvisi joined AstraZeneca in 2017 and was accountable for the global Respiratory & Immunology R&D organization spanning approximately 500 scientists across the UK, Sweden, the US, and Spain. During her tenure she built and advanced one of the industry's most innovative and productive early R&I portfolios, with end-to-end responsibility from target identification through Phase 3 investment decisions. Most recently, tozorakimab - a potential first-in-class IL-33 antibody that she championed from early preclinical development through the Phase 3 investment decision - met its primary endpoints in both the OBERON and TITANIA trials in COPD. The results, announced last month, have been widely recognized as landmark for the field and potentially transformational for COPD patients. Alongside her industry career, Maria has held a professorship at the National Heart & Lung Institute, Imperial College London - a position she continues to hold today. During her time leading the Imperial research group, she trained more than thirty PhD students and published over 250 peer-reviewed papers. She also served as Research Director of the European Respiratory Society (2013-2016) and founded IR Pharma, a contract research organization serving major pharmaceutical companies in the respiratory space. In her new role at Ailux, Maria will also establish and lead a UK research site, further expanding the company's presence in one of the world's leading centers for biomedical research and innovation. She is a Fellow of the European Respiratory Society, the British Pharmacological Society, and the Academy of Medical Sciences, and was named one of Endpoints News' "20 Outstanding Women in Biopharma" in 2021. "Maria is exactly the kind of scientific leader Ailux needs at this stage of our journey," said Alex Li, CEO of Ailux. "She has spent her career turning bold scientific hypotheses into medicines that reach patients - building programs from scratch, taking them through the clinic, and doing so at a scale that few have matched. We are building Ailux to go the full distance, and Maria's scientific leadership will be central to every step of that journey." "What drew me to Ailux is the genuine integration of AI and biology - not AI as a tool applied to conventional drug discovery, but as a co-equal foundation for how programs are conceived and built," said Professor Belvisi, CSO of Ailux. "I believe Ailux's platform and team give us a real opportunity to originate first-in-class and best-in-class medicines, and I am excited to join the team and work together to build a global company that can deliver transformative therapies to patients." About Ailux Ailux is an AI-native biotech company headquartered in Shanghai and a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company's global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027. SOURCE Ailux

Stock Titan
Apr 9th, 2026
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on ide849-imfinzi SCLC trial.

IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on ide849-imfinzi SCLC trial. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA's investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca's PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach. 8-K event classification. Item 8.01 - Other Events Key terms. clinical collaboration agreement, antibody-drug conjugate, Phase 1 clinical trial, programmed death-ligand 1 (PD-L1) inhibitor, +2 more 04/09/2026 - 06:01 AM Faq. What clinical collaboration did IDEAYA Biosciences (IDYA) announce with AstraZeneca? IDEAYA Biosciences entered a clinical collaboration agreement with AstraZeneca to study IDE849 with AstraZeneca's Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination trial, while AstraZeneca will supply Imfinzi, aiming to evaluate safety and efficacy in this difficult-to-treat cancer. What is IDE849 in the IDEAYA Biosciences (IDYA) and AstraZeneca study? IDE849 is IDEAYA Biosciences' investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate. It targets DLL3, which is reported to be upregulated in several solid tumor types, and is being evaluated for safety and efficacy in a global Phase 1 clinical trial program. Which cancers are targeted in IDEAYA Biosciences' IDE849 Phase 1 trial? The IDE849 Phase 1 trial focuses on DLL3 upregulated solid tumors, including extensive-stage small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma. These cancers have significant unmet medical need, and DLL3's limited expression in normal tissues makes it a promising therapeutic target. Who sponsors and supplies drugs in the IDEAYA (IDYA) and AstraZeneca collaboration? IDEAYA Biosciences will sponsor the clinical combination study evaluating IDE849 with AstraZeneca's Imfinzi. AstraZeneca will supply Imfinzi, a PD-L1 inhibitor, for the trial. This structure lets IDEAYA lead study operations while leveraging AstraZeneca's established immunotherapy agent. Where will IDEAYA Biosciences' IDE849 clinical trial enroll patients? IDEAYA's multi-site global Phase 1 clinical trial for IDE849 plans to enroll patients across North America, Europe, Australia, South America, and Asia. This broad geographic footprint is designed to access diverse patient populations with DLL3 upregulated solid tumors, including small cell lung cancer. Filing exhibits & attachments. 3 documents

Cision
Apr 9th, 2026
Result of AGM.

Result of AGM. 9 April 2026 Results of Annual General Meeting held on 9 April 2026 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. | / | Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes cast in total | Total votes cast as a % of issued share capital | Votes withheld | | 1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025 | 1,198,663,815 | 99.99% | 166,701 | 0.01% | 1,198,830,516 | 77.29% | 2,309,793 | | 2 | To confirm the 2025 interim dividends | 1,199,596,253 | 99.91% | 1,054,621 | 0.09% | 1,200,650,874 | 77.41% | 489,438 | | 3 | To appoint KPMG LLP as Auditor | 1,200,331,533 | 99.98% | 203,239 | 0.02% | 1,200,534,772 | 77.40% | 605,649 | | 4 | To authorise the Directors to agree the remuneration of the Auditor | 1,200,231,237 | 99.98% | 277,426 | 0.02% | 1,200,508,663 | 77.40% | 631,646 | | 5a | To re-elect Michel Demaré as a Director | 1,181,183,631 | 98.39% | 19,312,258 | 1.61% | 1,200,495,889 | 77.40% | 644,420 | | 5b | To re-elect Pascal Soriot as a Director | 1,188,466,505 | 99.00% | 12,056,196 | 1.00% | 1,200,522,701 | 77.40% | 617,611 | | 5c | To re-elect Aradhana Sarin as a Director | 1,191,427,943 | 99.30% | 8,391,362 | 0.70% | 1,199,819,305 | 77.36% | 1,321,004 | | 5d | To re-elect Philip Broadley as a Director | 1,171,470,116 | 97.59% | 28,983,447 | 2.41% | 1,200,453,563 | 77.40% | 686,746 | | 5e | To re-elect Euan Ashley as a Director | 1,197,441,098 | 99.75% | 3,022,489 | 0.25% | 1,200,463,587 | 77.40% | 676,722 | | 5f | To re-elect Birgit Conix as a Director | 1,200,028,460 | 99.96% | 428,931 | 0.04% | 1,200,457,391 | 77.40% | 683,030 | | 5g | To re-elect Rene Haas as a Director | 1,176,085,879 | 97.97% | 24,361,879 | 2.03% | 1,200,447,758 | 77.40% | 692,663 | | 5h | To re-elect Karen Knudsen as a Director | 1,200,091,469 | 99.97% | 370,843 | 0.03% | 1,200,462,312 | 77.40% | 678,109 | | 5i | To re-elect Diana Layfield as a Director | 1,199,711,377 | 99.94% | 755,622 | 0.06% | 1,200,466,999 | 77.40% | 673,422 | | 5j | To re-elect Anna Manz as a Director | 1,199,171,542 | 99.89% | 1,310,287 | 0.11% | 1,200,481,829 | 77.40% | 658,592 | | 5k | To re-elect Sheri McCoy as a Director | 1,181,129,650 | 98.39% | 19,334,808 | 1.61% | 1,200,464,458 | 77.40% | 675,963 | | 5l | To re-elect Tony Mok as a Director | 1,197,756,109 | 99.77% | 2,702,422 | 0.23% | 1,200,458,531 | 77.40% | 681,890 | | 5m | To re-elect Marcus Wallenberg as a Director | 993,713,162 | 83.80% | 192,121,282 | 16.20% | 1,185,834,444 | 76.46% | 15,305,980 | | 6 | To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025 | 1,161,885,452 | 96.78% | 38,608,771 | 3.22% | 1,200,494,223 | 77.40% | 646,086 | | 7 | To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020 | 1,186,833,063 | 98.89% | 13,376,194 | 1.11% | 1,200,209,257 | 77.38% | 930,948 | | 8 | To authorise limited political donations | 1,176,818,096 | 98.50% | 17,954,803 | 1.50% | 1,194,772,899 | 77.03% | 6,367,525 | | 9 | To authorise the Directors to allot shares | 1,115,450,202 | 92.92% | 84,989,076 | 7.08% | 1,200,439,278 | 77.40% | 701,146 | | 10 | To authorise the Directors to disapply pre-emption rights | 1,113,184,536 | 92.75% | 87,024,695 | 7.25% | 1,200,209,231 | 77.38% | 930,073 | | 11 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 1,053,612,673 | 87.78% | 146,670,037 | 12.22% | 1,200,282,710 | 77.39% | 856,594 | | 12 | To authorise the Company to purchase its own shares | 1,197,748,658 | 99.81% | 2,335,330 | 0.19% | 1,200,083,988 | 77.38% | 1,056,436 | | 13 | To reduce the notice period for general meetings | 1,108,104,727 | 92.31% | 92,307,790 | 7.69% | 1,200,412,517 | 77.40% | 727,904 | Nazneen Rahman retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, she will receive her pro-rata entitlement to non-executive director fees for the month of April 2026. No other remuneration payment or payment for loss of office will be made. A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Issued capital As at 7 April 2026, the number of issued shares of the Company was 1,550,988,781 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca Matthew Bowden Company Secretary AstraZeneca PLC This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

WTVR CBS 6
Apr 6th, 2026
New Virginia economic laws: Gov. Spanberger signs legislation on development projects.

New Virginia economic laws: Gov. Spanberger signs legislation on development projects. By: WTVR CBS 6 Web Staff Posted 12:27 PM, Apr 06, 2026 RICHMOND, Va. - Gov. Abigail Spanberger has signed another batch of legislation into Virginia law, the most recent bills focusing on economic development in the Commonwealth. A news release from the governor's office says the bills passed with bipartisan support and will bring 3,250 jobs to Virginia. "From my very first day in office, I have been working to create a stable business environment so companies can hire, expand, and continue to invest in our Commonwealth," said Gov. Spanberger. "I am signing these bills into law so we can continue to grow Virginia's economy and create opportunities for Virginians." The following bills focus on economic development: * HB1531 (Delegate Luke Torian), SB835 (Senator L. Louise Lucas) - Avio USA will invest more than $537 million and create more than 1,500 jobs in Pittsylvania, building solid rocket motors for the defense, tactile propulsion, missile systems, and commercial space sectors. * HB799 (Delegate Luke Torian), SB403 (Senator L. Louise Lucas) - Hitachi Energy will invest more than $457 million and create more than 825 jobs in Halifax to produce critical electrical grid infrastructure. * HB800 (Delegate Luke Torian), SB404 (Senator L. Louise Lucas) - Eli Lilly and Company will invest more than $2 billion and create more than 450 jobs in Goochland to manufacture active pharmaceutical ingredients for cancer, autoimmune, and other advanced therapies. * HB1076 (Delegate Amy Laufer), SB527 (Senator Creigh Deeds) - AstraZeneca will invest $4 billion and create 500 jobs in Albermarle to manufacture medication for chronic diseases and antibody-drug conjugates. "Attracting new businesses and jobs to Virginia is a core focus of my administration," Spanberger said. "I'm proud of the hundreds of millions of dollars in investment we have already announced this year. I look forward to continuing to work with legislators, local communities, and business leaders as we make clear that Virginia is the top state in the nation to grow or start a business." CBS 6 is committed to sharing community voices on this important topic. Email your thoughts to the CBS 6 Newsroom. : CONNECT WITH US

INACTIVE